ANZCTR search results

Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP targets during vasopressor therapy for shock in ICU are individualized based on patients’ own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings. Hypothesis We hypothesize that targeting a patient’s pre-illness MAP during management of shock can minimize the degree of MAP-deficit (measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU. Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality. Significance To date no major RCT has tested this strategy among ICU patients with shock. This pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care. This is an opportunity for the clinicians to support a clinical trial that aims to compare the effects of a simple intervention of individualized blood pressure targets over standard care for patients with shock in ICU.

The present study aims to assess the acceptability and feasibility of a recovery-orientated well-being group therapy program for people living with bipolar disorder that was developed to be specifically designed to be delivered via telehealth (Zoom platform) by clinicians using a randomised-controlled pilot design. It was hypothesised that by assessing weekly attendance, drop-out rates, homework compliance and qualitative interview data that the zoom-delivered program would be found to feasible and acceptable program for participants living with BD and that the telehealth platform would be viable as a form of delivery.

We are conducting a clinical trial to compare two different classes of footwear for managing adolescent kneecap pain. The participants will wear their allocated study shoes during all planned sport and exercise based activities over a 3 month period. The two different treatment groups in this study are: 1. Flat flexible shoes 2. Stable supportive shoes We will evaluate the effectiveness of the different footwear classes on pain and physical function at 3 months. Primary and secondary outcomes will be collected via online survey at baseline and 3 months. Our hypothesis is that flat flexible shoes, which have been shown to reduce kneecap loading in adolescents, will result in a greater improvement in kneecap pain for adolescents.

This project will use a short survey via text message to understand ongoing symptoms and functional impacts arising after COVID-19, influenza and a PCR negative control group. It aims to increase understanding of post-viral recovery amongst those who have had either COVID-19, influenza and other acute respiratory infections (ARIs), and provide Queensland Health with information on any difference between the burden of "long COVID" and a long recovery from influenza and other ARIs. The survey will be sent out to individuals who obtained test results across a four week period from late May to June 2022, which must be 12 weeks or more prior to the issuing of the initial survey, and 12 months prior to the second survey. The survey is based on a validated tool called the Post-COVID Functional Scale (PCFS). The results of the two groups are to be compared to ascertain the severity of long COVID when compared with the influenza-positive control group and those negative to these two illnesses (ie the group has "another ARI"). The findings may assist Queensland Health in any appropriate response to support those experiencing a prolonged recovery from COVID-19 and/or influenza. The Project Team is part of Queensland Health's COVID-19 System Response unit, which accesses the Notifiable Conditions System. The system houses information on COVID-19 and influenza positive PCRs, and people with a negative PCR for COVID-19.

This is a study that aims to identify patients that might be susceptible to prolonged requirement for opioids after painful surgery. It will do this by using facial recognition technology before surgery to see whether participants respond to a specialised pharmacologic intervention to minimise unnecessary opioid use. It will do so by comparing this intervention with usual care to see whether there is an overall reduction of days where opioid therapy is needed following surgery between two groups. One group will use information from Artificial Intelligence prior to surgery to identify facial characteristics predicting prolonged opioid requirement following surgery, Those with predicted prolonged opioid requirement will have postoperative pain managed in close conjunction with a pharmacist. They will be involved in a detailed program where they are reviewed regularly and, if circumstances are appropriate, have their opioid dose reduced proactively. This is known as pharmacy-led opioid de-escalation. It comprises management by an accredited clinical pharmacist providing an individualised plan aiming for detailed patient education together with opioid reduction of approximately 25-50% every (1-3) days. The plan will take pain intensity scores into consideration. Increasing pain intensity scores will result in no de-escalation, whilst unchanged and decreasing pain scores will result in reduction of opioid of approximately 25-50% every (1-3) days. The clinical pharmacist will also continue to closely follow progress of patients assigned to opioid de-escalation after discharge from hospital to continue the de-escalation pathway until cessation of all opioid analgesics, often working in conjunction with a family doctor. The other group will be randomly allocated to receive usual care for their postoperative pain. This comprises filming the participant but not acting on the results of the AI facial recognition analysis. All participants in this group will be subject to current practice whereby surgical residents (young doctors working with the surgical team) manage opioids after the acute recovery period using their existing knowledge with involvement of pharmacists who help with dispensing and provide basic education. Following discharge from hospital the family physician continues to provide follow-up. The main measure of the study will be the time in days of opioid requirement compared between the two groups.

This study will evaluate a tailored communication intervention, developed with people with brain cancer, for people with brain cancer and their families. Who is it for? You may be eligible for this study if you are an adult with a diagnosis of a primary brain tumour (including benign, lower-grade glioma and higher-grade glioma). Study details Participants will be randomly allocated to either the intervention or control group. The intervention group will have a combination of weekly individual and group sessions focused around communication strategies and resources, delivered by a speech pathologist. The control group will receive usual care by hospital speech pathologists, and will have the opportunity to access the tailored communication intervention once the intervention group have completed their assessments. All participants will be asked to complete questionnaires and interviews assessing their communication function and perception of the intervention over the study period. It is hoped that findings from this study will help optimise communication treatments for people with brain cancer, where communication impairments are highly prevalent.

This study aims to test the hypothesis that the body surface contacting 'Saiiv Morphic sensors' (singularly or in combination), can accurately detect haemodynamic signals compared to gold standard measurement techniques. The study will be recruiting patients with a confirmed diagnosis of Heart Failure, who are scheduled to have a Right Heart Catheter as standard of care. Participants who are enroled, will have their Right Heart Catheter as normal, with the addition of the Saiiv Morphic sensors being placed on various parts of their body to collect haemodynamic signals. Participants will also have the Saiiv Morphic sensors attached to them outside of the Right Heart Catheter procedure. Both of these sessions will compare the Saiiv Morphic sensors to the data collected by widely used Gold Standard devices.

In this project, we plan to recruit a cohort of women (the ‘MAMBO’ cohort) to establish the phenotype of women that are most likely to have a) large or small for gestational age offspring and b) new maternal metabolic disease (dysglycaemia, overweight/obesity, hypertension) that develops during pregnancy or within 12-18 months post-partum. These women will be recruited at 20 plus or minus 4 weeks gestation. The overall aim of this project is to develop a model that identifies a maternal phenotype that best predicts a mothers risk of giving birth to a metabolically prone child. The specific aims of this project are: (i) Aim 1: To observe the metabolic changes during pregnancy and post-partum in a cohort of offspring and to identify metabolically prone offspring defined as: • Offspring with birthweight equal to or greater than 90th centile on customized centile charts (large for gestational age; LGA) • Offspring with birthweight equal to or less than 10th centile on customized centile charts (small for gestational age; SGA). (ii) Aim 2: To observe the metabolic changes during pregnancy and post-partum in a cohort of mothers and to identify mothers with new metabolic disease that develops in pregnancy or 12-18 months post-partum defined as: - A composite of dysglycaemia outcomes - A composite of hypertension outcomes - A composite of body weight outcomes To facilitate long-term follow-up of the MAMBO cohort, we are collaborating with Generation Victoria (GenV: https://genv.org.au). GenV is aiming to recruit parallel cohorts of newborns and MAMBO neonates will be eligible to participate in the MAMBO follow-up.

This study is assessing whether mobile phone SMS messaging alone, and SMS bundles with links to videos, will affect how many people choose to complete the National Bowel Cancer Screening Program (NBCSP) test among 49 to 60-year-old general practice patients in Victoria and Queensland. Who is it for? You may be eligible for this study if you are aged between 49 to 60 years, you are eligible to receive the free National Bowel Cancer Screening Program test kit, your GP has agreed to participate in the study and you have access to a smartphone. Study details Participants will be randomly assigned to one of three groups. The first group will receive a single SMS message sent by their GP's practice 2 weeks prior to receiving their NBCSP test kit in the mail. The second group will receive a similar SMS message that also includes web links to a number of resources, including a message from their GP endorsing the free home test kit; an instructional video on how to do the kit; a video of relatable people talking about why it is important to do the kit; and an animation showing how to do the test. The third group will not receive a SMS message but will still receive the NBCSP test kit in the mail. Participants in the third group will be able to discuss the test with their GP as part of their usual care. It is hoped this research will determine whether SMS prompts about completing the NBCSP test kit impact on the number of people choosing to take up the screening test at home, which could increase early detection of bowel cancer.

There is limited information support for women when transitioning out of Australia's national breast cancer screening program (BreastScreen). Older women (70+ years) report reasons for no longer being reminded including being too old, the cost, and having a lesser risk of developing breast cancer. Some general practitioners also find it difficult to explain this information. The aim of this study is to examine the impact of information that provides older women with a rationale for no longer being reminded to participate in the BreastScreen program on informed choice.